Table 3 Reactivity of myositis-related autoantibodies in sera from patients with sporadic inclusion body myositis (sIBM) as determined by Euroline Autoimmune Inflammatory Myopathies 16 Ag (IgG) immunoblot (Euroimmun)
Myositis-related autoantibodies | sIBM patients | ||||
|---|---|---|---|---|---|
All (n = 75) | Anti-cN-1A-positive (n = 28) | Correlation to anti-cN-1A | |||
Positive | Positive | ||||
n | Frequency | n | Frequency | r | |
Anti-Ro-52 | 11 | 14.7% | 9 | 32.1% | 0.381a |
Anti-OJ | 1 | 1.3% | 1 | 3.6% | 0.312c |
Anti-EJ | 1 | 1.3% | 0 | 0.0% | Â |
Anti-PL-12 | 3 | 4.0% | 2 | 7.1% | Â |
Anti-PL-7 | 3 | 4.0% | 1 | 3.6% | Â |
Anti-SRP | 3 | 4.0% | 3 | 10.7% | 0.315b |
Anti-Jo-1 | 1 | 1.3% | 0 | 0.0% | Â |
Anti-PM-Scl75 | 1 | 1.3% | 0 | 0.0% | Â |
Anti-PM-Scl100 | 1 | 1.3% | 1 | 3.6% | Â |
Anti-Ku | 3 | 4.0% | 2 | 7.1% | Â |
Anti-SAE1 | 0 | 0.0% | 0 | 0.0% | Â |
Anti-NXP2 | 0 | 0.0% | 0 | 0.0% | Â |
Anti-MDA5 | 0 | 0.0% | 0 | 0.0% | Â |
Anti-TIF1Îł | 2 | 2.7% | 1 | 3.6% | Â |
Anti-Mi-2β | 1 | 1.3% | 0 | 0.0% |  |
Anti-Mi-2α | 0 | 0.0% | 0 | 0.0% |  |